Showing results (91-100 of 183) with videos related to
Sort By:
Pageof 19
Frontiers in Immunology|August 4, 2018
HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy InitiationIsaac Rosado-Sánchez, Inés Herrero-Fernández, Miguel Genebat, et al.Enfermedades Infecciosas Y Microbiologia Clinica|January 12, 2015
[Barriers to ART initiation in HIV infected subjects and with treatment indication in Spain. Why don't they start their treatment? Bridgap Study]Pompeyo Viciana-Fernández, Vicenç Falcó, Manuel Castaño, et al.HIV Clinical Trials|December 7, 2017
Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infectionChan-Loi Yong, Joseph C Gathe, Gabriele Knecht, et al.Enfermedades Infecciosas Y Microbiologia Clinica|September 2, 2014
Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adultsAntonio Javier Blasco, Josep M Llibre, Juan Berenguer, et al.AIDS (London, England)|August 6, 2015
Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced diseaseMaria Casadellà, Christian Manzardo, Marc Noguera-Julian, et al.Antiviral Therapy|May 11, 2011
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN TrialVicente Soriano, Keikawus Arastéh, Horacio Migrone, et al.Sexually Transmitted Infections|May 11, 2022
Detecting anal human papillomavirus infection in men who have sex with men living with HIV: implications of assay variabilityMontserrat Torres, Ana Silva-Klug, Elena Ferrer, et al.The Journal of Infectious Diseases|October 13, 2020
No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS Research Network, PreEC/RIS 62)Juan M Tiraboschi, Jhon Rojas, Henrik Zetterberg, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|September 5, 2006
A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimenMargaret A Johnson, Joseph C Gathe, Daniel Podzamczer, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 8, 2006
Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trialJose M Miro, Juan C Lopez, Daniel Podzamczer, et al.Pageof 19